- Exchange: NASDAQ CM
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
Chelsea Therapeutics International Ltd
+ Add to WatchlistCHTP:US
2.4500 USD 0.1300 5.04%As of 20:10:00 ET on 06/18/2013.
Snapshot for Chelsea Therapeutics International Ltd (CHTP)
| Open: | 2.5600 | Day's Range: | 2.3500 - 2.6200 | Volume: | 1,248,818 |
|---|---|---|---|---|---|
| Previous Close: | 2.5800 | 52wk Range: | 0.7000 - 2.7600 | 1-Yr Rtn: | +94.44% |
Key Statistics for CHTP
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.2700 |
| Est. EPS (USD) (12/2013) | -0.3330 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 164.36 |
| Shares Outstanding (M) | 67.09 |
| 30 Day Average Volume | 902,807 |
| Price/Book (mrq) | 7.2635 |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/07/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for CHTP
Company Profile & Key Executives for CHTP
Chelsea Therapeutics International Ltd. is a biopharmaceutical company developing a pipeline of low toxicity antifolate compounds engineered to have anti-inflammatory and anti-tumor activity. The Company's lead candidate is in development as a metabolically inert treatment alternative to Methotrexate for rheumatoid arthritis, psoriasis, and other disorders.
| Joseph G OlivetoInterim CEO | William D SchwietermanVP/Chief Medical Officer |
| L Arthur HewittVP/Chief Scientific Officer | J Nick RiehleVP:Administration/CFO |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
CHTP News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page